HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

TheOTCLab Looks To Gain A Foothold In Europe's OTC Market With FungeX

Executive Summary

Beginning with its home market, the Netherlands, and also France, consumer healthcare specialist TheOTCLab is looking to establish a pan-European presence in the region's foot-care market with its new FungeX range of nail fungus and athletes' foot products. 

Dutch consumer healthcare specialist TheOTCLab wants to take a slice of Europe's foot-care market with its new FungeX range of nail fungus and athlete's foot products.

Registered as self-care medical devices within European Union regulations, TheOTCLab’s FungeX Nail Fungus products are being launched initially in the Netherlands and France, supported by a “360 degree” marketing campaign, including in-store, television and social media advertising.

TheOTCLab described its FungeX Nail Fungus Plaster as a "revolutionary" medical device which provided an “effective and intensive treatment for nail fungus and discolored toenails.”

Supported by clinical research showing “visible results for 81% of users within several weeks,” the FungeX Plaster provided “natural care by the continuous release of active ingredients for a maximum of eight hours,” the firm explained.

The second product to be released as part of the new range, FungeX Athlete's Foot Socks, was the “ultimate” way to soothe red, sensitive and irritated skin between the toes and feet, TheOTCLab claimed.

“Up to 20% of the population suffers from athlete's foot” the narrator in TheOTCLab’s television advertisement for its FungeX Socks explains.

 

 

 

TheOTCLab's TV Ad For FungeX Athlete's Foot Socks
Open Media

FungeX “one size fits all” non-medicated socks treated the condition and its symptoms – itching, sensitive and irritated skin and unpleasant smell – in a “single and hygiene application” for the entire foot, the company said.

TheOTCLab’s FungeX range also currently included the Nail Fungus Brush 3in1 and Nail Fungus Pen 3in1 products.

Looking For Partners

Speaking exclusively to HBW Insight, TheOTCLab’s chief executive officer Albert Swane revealed that the firm was also looking for partners to roll out FungeX more widely across Europe.

“We are looking for distributors in Europe who can introduce our FungeX products beyond the Netherlands and France, for example in Spain, Portugal, the UK and the Nordics,” he explained.

To be ready for the new foot-care season in 2020, Swane continued, TheOTCLab was looking to launch in these other countries in the third quarter of 2019.

Based in the Dutch capital, Amsterdam, TheOTCLab marketed in addition to FungeX a basket of other consumer healthcare brands across Europe, including: the Kiyoko natural lip balm; the Kidsner range of natural throat medicines for children; the Detoxner IBS and Detox bowel-care products; the Earclin ear shower; the MenoRelax vaginal moisturizer; the Coughner sore throat spray and the Bitener anti-nail-bite pen.

Founded in 2016, TheOTCLab described itself as a “dynamic company constantly looking for new innovations,” active in “product development, export, in-licensing and distribution.”

“We are passionate about giving people worldwide access to natural, easy-to-use and safe healthcare,” the firm said on its website. “Dedicated to improving daily life, we develop quality and effective product innovations.”

 

 

 

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149108

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel